Comment
Author: Admin | 2025-04-28
Top-performing drugs that dominate the pharmaceutical industry View ListNCE-1 Patent Expiry in the Next 1 Year Identify opportunities as new chemical entity (NCE-1) patents approach expiry View ListRecently Granted Patents in EP Find the opportunity to file Oppositions View List Generic Launch Generic Release Date: Wakix's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 21, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application) Wakix Generics: There are no approved generic versions for Wakix as of now. Alternative Brands for Wakix Wakix which is used for treating cataplexy in patients with narcolepsy., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively. Drug Owner Drug Name Treatment Area Jazz Pharms Xyrem Used for treating patients with narcolepsy and reducing excessive daytime sleepiness and cataplexy when administered with specific medications. About Wakix Wakix is a drug owned by Harmony Biosciences Llc. It is used for treating cataplexy in patients with narcolepsy. Wakix uses Pitolisant Hydrochloride as an active ingredient. Wakix was launched by Harmony in 2019. Wakix was approved by FDA for market use on 14 August, 2019. NCE-1 date: NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Wakix is 14 August, 2019, its NCE-1 date is estimated to be 15 August, 2023. Treatment: Wakix is used for treating cataplexy in patients with narcolepsy. Dosage: Wakix is available in tablet form for oral use. Given below is detailed information on Dosage - Strength Dosage Form Availability Application Pathway EQ 4.45MG BASE TABLET Prescription ORALEQ 17.8MG BASE TABLET Prescription ORAL Related content Have Questions?
Add Comment